Advancing a new therapeutic class to market requires a balance of strong science, solid IP protection, and a regulatory path that supports early access. Hunter Land (CEO) shares how Lupvindol is progressing its CBD–corticosteroid combinations for canine IBD and equine osteoarthritis through compelling efficacy data, robust patent strategy, and the FDA’s expanded conditional approval route.
Session Topics:
Intellectual Property
CBD
Canine
Equine
Osteoarthritis
Conditional Approval
Regulatory Approval
Speaker(s):
Hunter Land
CEO
Lupvindol Bioscience
Time:
1:55pm - 2:15pm
Agenda Track No.:
Track 3
Summary:
Session Will be Recorded - Attend live or Watch On-Demand
Session Type:
General Session (Presentation)
Force Inline Description:
0